Impact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study

被引：0
|
作者：
Yamazaki, K. [1 ]
Satoh, T. [2 ]
Komatsu, Y. [3 ]
Taguchi, T. [4 ]
Sunaga, Y. [5 ]
Yoshino, T. [6 ]
机构：
[1] Shizuoka Canc Ctr, Oncol, Surg, Gastroenterol, Sunto Gun, Japan
[2] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
[3] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
[4] Sanofi Japan, Med, Tokyo, Japan
[5] Sanofi Japan, Biostat & Programming, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
187P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
    Santoro, A.
    Comandone, A.
    Rimassa, L.
    Granetti, C.
    Lorusso, V.
    Oliva, C.
    Ronzoni, M.
    Siena, S.
    Zuradelli, M.
    Mari, E.
    Pressiani, T.
    Carnaghi, C.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1888 - 1893
  • [22] Phase I/II Study of FOLFIRI in Japanese Patients with Advanced Colorectal Cancer
    Yamashita, Keishi
    Nagashima, Fumio
    Fujita, Ken-ichi
    Yamamoto, Wataru
    Endo, Hisashi
    Miya, Toshimichi
    Narabayashi, Masaru
    Kawara, Kaori
    Akiyama, Yuko
    Ando, Yuichi
    Ando, Masahiko
    Sasaki, Yasutsuna
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 204 - 209
  • [23] Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study
    Piringer, Gudrun
    Thaler, Josef
    Anchisi, Sandro
    Geffriaud-Ricouard, Christine
    Gueldner, Max
    Scholten, Felicitas
    Derigs, Hans-Guenter
    Bohanes, Pierre
    Gruenberger, Birgit
    Schwarz, Leonora
    von Moos, Roger
    Hofheinz, Ralf-Dieter
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (08)
  • [24] Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
    Yamada, Yunami
    Matsuhashi, Nobuhisa
    Fujii, Hironori
    Makiyama, Akitaka
    Iihara, Hirotoshi
    Takahashi, Takao
    Watanabe, Daichi
    Kiyama, Shigeru
    Kobayashi, Ryo
    Suzuki, Akio
    Yoshida, Kazuhiro
    ANTICANCER RESEARCH, 2021, 41 (01) : 533 - 541
  • [25] Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
    Fotios Loupakis
    Herbert I. Hurwitz
    Leonard Saltz
    Dirk Arnold
    Axel Grothey
    Quynh Lan Nguyen
    Stuart Osborne
    Jonathan Talbot
    Stefanie Srock
    Heinz-Josef Lenz
    British Journal of Cancer, 2018, 119 : 1451 - 1455
  • [26] Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
    Loupakis, Fotios
    Hurwitz, Herbert, I
    Saltz, Leonard
    Arnold, Dirk
    Grothey, Axel
    Quynh Lan Nguyen
    Osborne, Stuart
    Talbot, Jonathan
    Srock, Stefanie
    Lenz, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1451 - 1455
  • [27] A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer
    Ando, Koji
    Satake, Hironaga
    Shimokawa, Mototsugu
    Yasui, Hisateru
    Negoro, Yuji
    Kinjo, Tatsuya
    Kizaki, Junya
    Baba, Kenji
    Orita, Hiroyuki
    Hirata, Keiji
    Sakamoto, Sanae
    Makiyama, Akitaka
    Saeki, Hiroshi
    Tsuji, Akihito
    Baba, Hideo
    Oki, Eiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 514 - 523
  • [28] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [29] KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
    Gutierrez, Cristina
    Rodriguez, Javier
    Patino-Garcia, Ana
    Garcia-Foncillas, Jesus
    Salgado, Josefa
    ONCOLOGY LETTERS, 2013, 6 (05) : 1343 - 1345
  • [30] Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study
    Strickler, John H.
    Cubillo, Antonio
    Liang, Jin-Tung
    Matrana, Marc
    Kozloff, Mark
    Lowe, Thomas
    Blaney, Martha
    Sahtout, Mohammad
    Naumovski, Louie
    Wainberg, Zev A.
    FUTURE ONCOLOGY, 2022, 18 (27) : 3011 - 3020
12345